AbolerIS Pharma Appoints Philippe Alen Chief Business Officer

AbolerIS Pharma (AbolerIS), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune and inflammatory diseases, today announced the appointment of Philippe Alen as Chief Business Officer (CBO). 

With over twenty-five years of business development, licensing, M&A, and alliance management experience, Alen will drive Aboleris’ strategic partnerships, financing activities, and corporate growth initiatives.

In his new role, Alen will lead Aboleris’ business development and corporate strategy functions, working closely with the executive leadership team to translate the company’s deep immunology expertise into collaborations and value-creating transactions.

His broad industry experiences include roles of increasing responsibility at major life-sciences companies, including Johnson & Johnson Innovative Medicine, Bayer, and Galapagos NV. He has also served on the Board of Directors of Fibrocor Therapeutics.

Alen’s expertise covers search & evaluation, licensing, M&A, equity investment, and alliance management, with experience in therapeutic areas such as infectious diseases, vaccines, cardio-metabolic, women’s health, oncology, and immunology.  

“Philippe’s proven track record in deal-making and strategic business development is an excellent fit for Aboleris’ ambition to become a key player in inflammatory, autoimmune, and degenerative diseases,” said Dr. Ann Meulemans, CEO of Aboleris Pharma. “His leadership will help accelerate our partnerships and financing efforts as we advance our pipeline through the clinic and toward patients in need.”